Endra Life Sciences gets five new international patents

ANN ARBOR–The Ann Arbor medical device developer Endra Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of five new patents, including three in Europe and two in China.

Endra’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the thermo-acoustic enhanced ultrasound (TAEUS) system with its novel thermoacoustic technology.

“With the issuance of these five patents, we’ve reached a significant milestone of 80 global patents,” said Francois Michelon, Endra’s chairman and CEO. “Our extensive IP portfolio safeguards and sets apart Endra’s thermoacoustic technology in areas of high unmet clinical need. We’re actively enhancing our intellectual property to secure our technology in key global markets and exploring licensing opportunities for indications beyond our core focus, opening further growth avenues for the company.”

The following five patents were issued:

  • European Patent No. EP4051151 (the ‘151 patent), titled “Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same,” covers a radio frequency applicator device and system for providing reliable RF energy to a target area of tissue. Specifically, the ‘151 patent structurally defines Endra’s solution to providing RF energy to targeted tissue regions for applications, such as liver fat quantification.
  • European Patent No. EP4037554, titled “Method and System for Determining a Material Type of an Object of Interest,” protects Endra’s method and system for determining a material type by utilizing TAEUS. The patent has potential application beyond liver measurements, which may include outside the human body.
  • European Patent No. EP4037551 (the ‘551 patent), titled “Method and System for Determining a Parameter of a Material of Interest,” relates to a novel method for determining at least one parameter of interest of a material utilizing TAEUS. Examples of potential parameters of interest include the Grüneisen parameter, which is the ratio of thermal pressure to thermal energy and conductivity. In addition, the ‘551 patent expands the imaging potential for the TAEUS technology outside the human body for select applications, such as material testing and identification.
  • The Chinese National Intellectual Property Administration issued ENDRA two new patents, ZL2019800868227 (the ‘227 patent) and ZL202110813939X (the ‘39X patent), both titled “Method and System for Monitoring Tissue Temperature.” The ‘227 and ‘39X patents relate to novel methods and systems for monitoring tissue temperature with TAEUS during surgical procedures, such as thermotherapy and cryotherapy.

Endra’s TAEUS technology characterizes tissue like an MRI, but at 1/40th the cost and at the point of patient care. TAEUS is designed to work in concert with over 700,000 ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, Endra is exploring several other clinical applications of TAEUS, including tissue temperature imaging during energy-based surgical procedures. For information, visit www.endrainc.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.